JODI FUEHRER: Open Payments
NPI 1982861589 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$22,283 in 88 payments from 14 companies in 2025. Trend: 2023 $929 · 2024 $1,271 · 2025 $22,283
Speaker / faculty: $18,925Travel & lodging: $1,853Food & beverage: $1,505
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 54 | $21,583 |
| ABBVIE INC. | 10 | $165 |
| Otsuka America Pharmaceutical, Inc. | 7 | $161 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $101 |
| E.R. Squibb & Sons, L.L.C. | 4 | $59 |
| Lundbeck LLC | 3 | $56 |
| Noven Therapeutics, LLC | 2 | $34 |
| Biogen, Inc. | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Alkermes, Inc. | 1 | $19 |
Products named: Epclusa, REXULTI, VRAYLAR, Biktarvy, CAPLYTA, COBENFY, Xelstrym, MAVYRET.
Industry payments across NE — which companies pay providers there.
